“Biosurgery products are used to aid surgeries and repair weakened and damaged tissues and bones of a body. The biosurgery market is majorly driven by the rising number of surgeries owing to the increasing rate of obesity and other lifestyle disorders, increasing participation in sports leading to sports-related injuries, and growing aging population. However, lack of reimbursement for these products and the increasing cost of surgical procedures are expected to restrain the growth of this market during the forecast period.
The biosurgery market in this report is broadly segmented on the basis of type and application. On the basis of type, the market is segmented into sealants, hemostatic agents, adhesion barriers, soft-tissue attachments, bone-graft substitutes, and staple-line reinforcement agents. On the basis of application, the market is segmented into neurological surgeries, cardiovascular surgeries, general surgeries, orthopedic surgeries, thoracic surgeries, gynecology surgeries, urology surgeries, and reconstructive surgeries.
The global biosurgery market is expected to reach $25,635.01 million by 2020, growing at a CAGR of 8.8% during the forecast period (2015 to 2020). Rising investments in R&D leading to development of innovative products in this space is propelling the growth of this market. Biosurgery products are finding increasing applications in neurological surgeries.
Developed markets like North America and Europe will show sluggish growth, while emerging markets like Asia-Pacific and RoW (Latin America) are expected to witness strong growth during the forecast period. Growth in the Asia-Pacific and RoW markets will be majorly driven by countries such as China, Korea, Russia, and Brazil owing to the rising government investments in these countries, presence of a large patient population, and the increasing focus of leading players to capture growth opportunities in these markets.
Some of the prominent players in this market include Baxter International Inc. (U.S.), C.R. Bard (U.S.), Johnson & Johnson (U.S.), Covidien plc (Ireland), Sanofi Group (France), B. Braun Melsungen AG (Germany), Atrium Medical Corporation (U.S.), Cryolife, Inc. (U.S.), Stryker Corporation (U.S.), and Hemostasis, LLC (U.S.). Mergers and acquisitions, expansions, and new product launches are some of the strategies adopted by these players to sustain and enhance their presence in this market.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms, and allow them to gauge the pulse of the market, which in turn will help firms garner greater market shares. Firms purchasing the report could use one or a combination of the below-mentioned strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for increasing their market shares.
The report provides insights on the following pointers:
ï® Market Penetration: Comprehensive information on the product portfolios offered by top players in the biosurgery market. The report analyzes the biosurgery market by type and application
ï® Product Development/Innovation: Detailed insights on upcoming trends, research and development activities, and new product launches in the biosurgery market
ï® Market Development: Comprehensive information about lucrative emerging markets by product, application, and region
ï® Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the biosurgery market
ï® Competitive Assessment: In-depth assessment of market shares, growth strategies, products, manufacturing capabilities, and SWOT analyses of leading players in the biosurgery market
”
“TABLE OF CONTENTS
1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 16
1.3.2 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 17
1.5 LIMITATIONS 18
1.6 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH DATA 19
2.1.1 SECONDARY DATA 20
2.1.1.1 Key data from secondary sources 20
2.1.2 PRIMARY DATA 20
2.1.2.1 Key data from primary sources 21
2.1.2.2 Key industry insights 21
2.1.2.3 Breakdown of primary interviews 22
2.2 MARKET SIZE ESTIMATION 22
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 24
2.4 MARKET SHARE ESTIMATION 25
2.5 ASSUMPTIONS FOR THE STUDY 25
3 EXECUTIVE SUMMARY 26
4 PREMIUM INSIGHTS 30
4.1 GROWTH POTENTIAL OF THE BIOSURGERY MARKET 30
4.2 ASIA-PACIFIC: BIOSURGERY MARKET, BY PRPDUCT TYPE (2014) 31
4.3 BIOSURGERY MARKET: BY PRODUCTS IN U.S. 32
4.4 BIOSURGERY MARKET, REGIONAL MIX 32
4.5 BIOSURGERY MARKET: DEVELOPED VS. DEVELOPING MARKETS 33
5 MARKET OVERVIEW 34
5.1 INTRODUCTION 35
5.2 MARKET SEGMENTATION 35
5.2.1 BY PRODUCT 35
5.2.2 BY APPLICATION 36
5.2.3 BY REGION 36
5.3 MARKET DYNAMICS 37
5.3.1 MARKET DRIVERS 38
5.3.1.1 Rising number of surgeries 38
5.3.1.2 Increasing incidence of sports-related injuries and spinal problems 38
5.3.1.3 Rapid rise in aging population 39
5.3.2 MARKET RESTRAINTS 40
5.3.2.1 Little-to-no reimbursements for biosurgery products 40
5.3.3 MARKET OPPORTUNITIES 41
5.3.3.1 Improving healthcare systems in emerging markets with growing public & private investments 41
5.3.4 MARKET CHALLENGES 42
5.3.4.1 High price of biosurgery products & rising cost of surgical procedures 42
6 INDUSTRY INSIGHTS 44
6.1 INTRODUCTION 44
6.2 INDUSTRY TRENDS 44
6.2.1 GROWING PREFERENCE FOR BIOLOGICAL MESHES IN SURGICAL PROCEDURES 44
6.2.2 GROWING NUMBER OF ACQUISITIONS IN THE BIOSURGERY MARKET 45
6.3 PORTER’S FIVE FORCES ANALYSIS 46
6.3.1 THREAT OF NEW ENTRANTS 46
6.3.2 THREAT OF SUBSTITUTES 47
6.3.3 BARGAINING POWER OF SUPPLIERS 47
6.3.4 BARGAINING POWER OF BUYERS 47
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 48
6.4 STRATEGIC BENCHMARKING 48
7 BIOSURGERY MARKET, BY PRODUCT 51
7.2 INTRODUCTION 52
7.3 SURGICAL SEALANTS 53
7.3.1 FIBRIN SEALANTS 55
7.3.2 SYNTHETIC AGENTS/CYANOACRYLATES 56
7.3.3 COLLAGEN-BASED SEALANTS 57
7.3.4 TISSUE-ADHESIVE GLUES 58
7.4 HEMOSTATIC AGENTS 60
7.5 ADHESION BARRIERS 61
7.6 SOFT-TISSUE ATTACHMENTS (SOFT-TISSUE PATCH/MESH) 62
7.6.1 SYNTHETIC MESH 63
7.6.2 BIOLOGICAL MESH 64
7.6.2.1 Allografts 66
7.6.2.2 Xenografts 67
7.7 BONE-GRAFT SUBSTITUTES 68
7.7.1 BONE-ALLOGRAFTS 70
7.7.2 DEMINERALIZED BONE MATRIX (DBM) 71
7.7.3 BONE MORPHOGENETIC PROTEINS (BMP) 72
7.7.4 SYNTHETIC BONE-GRAFTS 73
7.8 STAPLE-LINE REINFORCEMENT AGENTS 74
8 BIOSURGERY MARKET, BY APPLICATION 76
8.1 INTRODUCTION 77
8.2 NEUROLOGICAL SURGERIES 78
8.3 CARDIOVASCULAR SURGERIES 80
8.4 GENERAL SURGERIES 82
8.5 ORTHOPEDIC SURGERIES 83
8.6 THORACIC SURGERIES 85
8.7 GYNECOLOGY SURGERIES 86
8.8 UROLOGY SURGERIES 87
8.9 RECONSTRUCTIVE SURGERIES 89
9 BIOSURGERY MARKET, BY REGION 91
9.1 INTRODUCTION 92
9.2 NORTH AMERICA 94
9.2.1 U.S. 97
9.2.2 CANADA 98
9.3 EUROPE 100
9.3.1 GERMANY 103
9.3.2 U.K. 104
9.3.3 FRANCE 106
9.3.4 ITALY 107
9.3.5 SPAIN 109
9.3.6 REST OF EUROPE (ROE) 110
9.4 ASIA-PACIFIC (APAC) 112
9.4.1 JAPAN 115
9.4.2 CHINA 116
9.4.3 INDIA 118
9.4.4 REST OF ASIA-PACIFIC (ROAPAC) 119
9.5 REST OF THE WORLD (ROW) 121
9.5.1 LATIN AMERICA 122
9.5.2 MIDDLE EAST AND AFRICA 124
10 COMPETITIVE LANDSCAPE 126
10.1 OVERVIEW 126
10.2 MARKET SHARE ANALYSIS 128
10.2.1 SEALANTS, HEMOSTATIC AGENTS, ADHESION BARRIERS, AND STAPLE-LINE REINFORCEMENT AGENTS 128
10.2.2 BONE-GRAFT SUBSTITUTES 129
10.2.3 SOFT TISSUE ATTACHMENTS 130
10.3 COMPETITIVE SITUATION AND TRENDS 131
10.3.1 MERGERS & ACQUISITIONS 132
10.3.2 NEW PRODUCT LAUNCHES 133
10.3.3 AGREEMENTS, PARTNERSHIPS, AND ALLIANCES 134
10.3.4 EXPANSIONS 135
10.3.5 APPROVALS 136
11 COMPANY PROFILES 138
(Overview, Financials, Products & Services, Strategy, & Developments)*
11.1 INTRODUCTION 138
11.2 BAXTER INTERNATIONAL INC. 139
11.3 JOHNSON & JOHNSON 142
11.4 C.R. BARD, INC. 146
11.5 COVIDIEN PLC. 150
11.6 SANOFI GROUP 154
11.7 B. BRAUN MELSUNGEN AG 157
11.8 ATRIUM MEDICAL CORPORATION (A PART OF GETINGE GROUP) 159
11.9 CRYOLIFE, INC. 161
11.10 HEMOSTASIS, LLC 163
11.11 STRYKER CORPORATION 164
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.
12 APPENDIX 166
12.1 INSIGHTS OF INDUSTRY EXPERTS 166
12.2 DISCUSSION GUIDE 167
12.3 OTHER DEVELOPMENTS 170
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 171
12.5 AVAILABLE CUSTOMIZATIONS 172
12.6 RELATED REPORTS 173
“
“LIST OF TABLES
TABLE 1 BIOSURGERY MARKET: ANALYSIS OF DRIVERS 40
TABLE 2 BIOSURGERY MARKET: ANALYSIS OF RESTRAINTS 41
TABLE 3 BIOSURGERY MARKET: ANALYSIS OF OPPORTUNITIES 42
TABLE 4 BIOSURGERY MARKET: ANALYSIS OF CHALLENGES 43
TABLE 5 PRODUCT PORTFOLIO ANALYSIS: BIOSURGERY MARKET 48
TABLE 6 GLOBAL BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013–2020 ($MILLION) 53
TABLE 7 GLOBAL SURGICAL SEALANTS MARKET SIZE, BY PRODUCT TYPE,
2013–2020 ($MILLION) 54
TABLE 8 GLOBAL SURGICAL SEALANTS MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 54
TABLE 9 GLOBAL FIBRIN SEALANTS MARKET SIZE, BY COUNTRY, 2013–2020 ($MILLION) 55
TABLE 10 GLOBAL SYNTHETIC AGENTS/CYANOACRYLATES MARKET SIZE,
BY COUNTRY, 2013–2020 ($MILLION) 57
TABLE 11 GLOBAL COLLAGEN-BASED SEALANTS MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 58
TABLE 12 GLOBAL TISSUE ADHESIVE GLUES MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 59
TABLE 13 GLOBAL HEMOSTATIC AGENTS MARKET SIZE , BY COUNTRY,
2013–2020 ($MILLION) 60
TABLE 14 GLOBAL ADHESION BARRIERS MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 61
TABLE 15 GLOBAL SOFT-TISSUE PATCHES/MESHES MARKET SIZE,
BY PRODUCT TYPE, 2013–2020 ($MILLION) 62
TABLE 16 GLOBAL SOFT-TISSUE PATCHES/MESHES MARKET SIZE,
BY COUNTRY, 2013–2020 ($MILLION) 63
TABLE 17 GLOBAL SYNTHETIC MESH MARKET SIZE, BY COUNTRY, 2013–2020 ($MILLION) 64
TABLE 18 GLOBAL BIOLOGICAL MESH MARKET SIZE, BY PRODUCT TYPE,
2013–2020 ($MILLION) 65
TABLE 19 GLOBAL BIOLOGICAL MESH MARKET SIZE, BY COUNTRY, 2013–2020 ($MILLION) 65
TABLE 20 GLOBAL ALLOGRAFTS MARKET SIZE, BY COUNTRY, 2013–2020 ($MILLION) 66
TABLE 21 GLOBAL XENOGRAFTS MARKET SIZE, BY COUNTRY, 2013–2020 ($MILLION) 67
TABLE 22 GLOBAL BONE-GRAFT SUBSTITUTES MARKET SIZE, BY PRODUCT TYPE,
2013–2020 ($MILLION) 68
TABLE 23 GLOBAL BONE-GRAFT SUBSTITUTES MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 69
TABLE 24 GLOBAL BONE ALLOGRAFTS MARKET SIZE, BY COUNTRY, 2013–2020 ($MILLION) 70
TABLE 25 GLOBAL DBM MARKET SIZE, BY COUNTRY, 2013–2020 ($MILLION) 71
TABLE 26 GLOBAL BMP MARKET SIZE, BY COUNTRY, 2013–2020 ($MILLION) 72
TABLE 27 GLOBAL SYNTHETIC BONE-GRAFTS MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 73
TABLE 28 GLOBAL STAPLE-LINE REINFORCEMENT AGENTS MARKET SIZE,
BY COUNTRY, 2013–2020 ($MILLION) 74
TABLE 29 GLOBAL BIOSURGERY MARKET SIZE, BY APPLICATION, 2013–2020 ($MILLION) 78
TABLE 30 GLOBAL BIOSURGERY MARKET SIZE FOR NEUROLOGICAL SURGERIES,
BY COUNTRY, 2013–2020 ($MILLION) 79
TABLE 31 GLOBAL BIOSURGERY MARKET SIZE FOR CARDIOVASCULAR SURGERIES,
BY COUNTRY, 2013–2020 ($MILLION) 81
TABLE 32 GLOBAL BIOSURGERY MARKET SIZE FOR GENERAL SURGERIES,
BY COUNTRY, 2013–2020 ($MILLION) 82
TABLE 33 GLOBAL BIOSURGERY MARKET SIZE FOR ORTHOPEDIC SURGERIES,
BY COUNTRY, 2013–2020 ($MILLION) 84
TABLE 34 GLOBAL BIOSURGERY MARKET SIZE FOR THORACIC SURGERIES,
BY COUNTRY, 2013–2020 ($MILLION) 85
TABLE 35 GLOBAL BIOSURGERY MARKET SIZE FOR GYNECOLOGY SURGERIES,
BY COUNTRY, 2013–2020 ($MILLION) 86
TABLE 36 GLOBAL BIOSURGERY MARKET SIZE FOR UROLOGY SURGERIES,
BY COUNTRY, 2013–2020 ($MILLION) 88
TABLE 37 GLOBAL BIOSURGERY MARKET SIZE FOR RECONSTRUCTIVE SURGERIES,
BY COUNTRY, 2013–2020 ($MILLION) 90
TABLE 38 GLOBAL BIOSURGERY MARKET, BY REGION, 2013-2020 ($MILLION) 92
TABLE 39 NORTH AMERICA: BIOSURGERY MARKET SIZE, BY COUNTRY,
2013-2020 ($MILLION) 94
TABLE 40 NORTH AMERICA: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE,
2013-2020 ($MILLION) 94
TABLE 41 NORTH AMERICA: BIOSURGERY MARKET SIZE, BY APPLICATION,
2013-2020 ($MILLION) 95
TABLE 42 U.S.: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 97
TABLE 43 U.S.: BIOSURGERY MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 98
TABLE 44 CANADA: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 99
TABLE 45 CANADA: BIOSURGERY MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 99
TABLE 46 EUROPE: BIOSURGERY MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION) 100
TABLE 47 EUROPE: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 101
TABLE 48 EUROPE: BIOSURGERY MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 101
TABLE 49 GERMANY: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 103
TABLE 50 GERMANY: BIOSURGERY MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 104
TABLE 51 U.K.: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 105
TABLE 52 U.K.: BIOSURGERY MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 105
TABLE 53 FRANCE: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 106
TABLE 54 FRANCE: BIOSURGERY MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 107
TABLE 55 ITALY: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 108
TABLE 56 ITALY: BIOSURGERY MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 108
TABLE 57 SPAIN: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 109
TABLE 58 SPAIN: BIOSURGERY MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 110
TABLE 59 ROE: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 111
TABLE 60 ROE: BIOSURGERY MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 111
TABLE 61 APAC: BIOSURGERY MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION) 112
TABLE 62 APAC: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 113
TABLE 63 APAC: BIOSURGERY MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 113
TABLE 64 JAPAN: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 115
TABLE 65 JAPAN: BIOSURGERY MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 116
TABLE 66 CHINA: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 117
TABLE 67 CHINA: BIOSURGERY MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 117
TABLE 68 INDIA: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 118
TABLE 69 INDIA: BIOSURGERY MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 119
TABLE 70 ROAPAC: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 120
TABLE 71 ROAPAC: BIOSURGERY MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 120
TABLE 72 ROW: BIOSURGERY MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION) 121
TABLE 73 ROW: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 121
TABLE 74 ROW: BIOSURGERY MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 122
TABLE 75 LATIN AMERICA: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE,
2013-2020 ($MILLION) 123
TABLE 76 LATIN AMERICA: BIOSURGERY MARKET SIZE, BY APPLICATION,
2013-2020 ($MILLION) 123
TABLE 77 MIDDLE EAST AND AFRICA: BIOSURGERY MARKET SIZE, BY PRODUCT TYPE,
2013-2020 ($MILLION) 124
TABLE 78 MIDDLE EAST AND AFRICA: BIOSURGERY MARKET SIZE, BY APPLICATION,
2013-2020 ($MILLION) 125
TABLE 79 GROWTH STRATEGY MATRIX, 2011–2015 127
TABLE 80 MERGERS & ACQUISITIONS, 2011–2015 132
TABLE 81 NEW PRODUCT LAUNCHES, 2011–2015 133
TABLE 82 AGREEMENTS, PARTNERSHIPS, AND ALLIANCES, 2011–2015 134
TABLE 83 EXPANSIONS, 2011–2015 135
TABLE 84 APPROVALS, 2011–2015 136
“
“LIST OF FIGURES
FIGURE 1 GLOBAL BIOSURGERY MARKET 16
FIGURE 2 RESEARCH DESIGN 19
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 22
FIGURE 4 BOTTOM-UP APPROACH 23
FIGURE 5 TOP-DOWN APPROACH 23
FIGURE 6 DATA TRIANGULATION METHODOLOGY 24
FIGURE 7 GLOBAL BIOSURGERY MARKET, BY PRODUCT TYPE, 2015 VS. 2020 ($ MILLION) 26
FIGURE 8 GLOBAL BIOSURGERY MARKET SIZE, BY APPLICATION, 2015 VS. 2020 ($ MILLION) 27
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF THE BIOSURGERY MARKET, 2014 28
FIGURE 10 HIGH-GROWTH ASIA-PACIFIC COUNTRIES IN THE GLOBAL BIOSURGERY MARKET, 2014 29
FIGURE 11 INCREASING RATE OF OBESITY AND OTHER LIFESTYLE DISORDERS TO DRIVE MARKET GROWTH 30
FIGURE 12 SOFT TISSUE ATTACHMENTS SEGMENT COMMANDED A MAJOR SHARE OF THE ASIA-PACIFIC BIOSURGERY MARKET 31
FIGURE 13 STAPLE-LINE REINFORCEMENT AGENTS IS THE FASTEST GROWING BIOSURGERY PRODUCTS SEGMENT DURING THE FORECAST PERIOD 32
FIGURE 14 NORTH AMERICA TO DOMINATE THE BIOSURGERY MARKET DURING THE FORECAST PERIOD 32
FIGURE 15 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH DURING THE FORECAST PERIOD 33
FIGURE 16 BIOSURGERY MARKET SEGMENTATION, BY PRODUCT 35
FIGURE 17 BIOSURGERY MARKET SEGMENTATION, BY APPLICATION 36
FIGURE 18 BIOSURGERY MARKET SEGMENTATION, BY REGION 36
FIGURE 19 BIOSURGERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES 37
FIGURE 20 DEMOGRAPHIC GROWTH TRENDS OF THE ELDERLY POPULATION 39
FIGURE 21 MAJOR TRENDS IN THE BIOSURGERY MARKET 44
FIGURE 22 PORTER’S FIVE FORCES ANALYSIS 46
FIGURE 23 STAPLE-LINE REINFORCEMENT AGENTS IS THE FASTEST-GROWING SEGMENT IN THE BIOSURGERY MARKET 52
FIGURE 24 RECONSTRUCTIVE SURGERY, THE FASTEST-GROWING APPLICATION SEGMENT IN THE MARKET 77
FIGURE 25 BIOSURGERY MARKET SIZE, BY COUNTRY/REGION, 2015 VS. 2020 93
FIGURE 26 BIOSURGERY MARKET SHARE, BY REGION, 2014 VS. 2020 93
FIGURE 27 NORTH AMERICAN BIOSURGERY MARKET: INCREASING RATE OF OBESITY AND GROWING AGING POPULATION TO DRIVE MARKET GROWTH 96
FIGURE 28 GERMANY – A MAJOR MARKET FOR BIOSURGERY PRODUCTS 102
FIGURE 29 CHINA IS THE FASTEST GROWING BIOSURGERY MARKET IN ASIA-PACIFIC REGION 114
FIGURE 30 COMPANIES ADOPTED MERGERS AND ACQUISITIONS AS THEIR KEY GROWTH STRATEGY 126
FIGURE 31 MARKET SHARE ANALYSIS FOR SEALANTS, HEMOSTATIC AGENTS, ADHESION BARRIERS, AND STAPLE-LINE REINFORCEMENT AGENTS, BY KEY PLAYER, 2014 128
FIGURE 32 MARKET SHARE ANALYSIS FOR BONE-GRAFT SUBSTITUTES, BY KEY PLAYER, 2014 129
FIGURE 33 MARKET SHARE ANALYSIS FOR SOFT TISSUE REPAIR, BY KEY PLAYER, 2014 130
FIGURE 34 BATTLE FOR MARKET SHARE: MERGERS AND ACQUISITIONS WAS THE KEY STRATEGY ADOPTED BY PROMINENT PLAYERS 131
FIGURE 35 GEOGRAPHIC REVENUE MIX OF MAJOR PLAYERS 138
FIGURE 36 COMPANY SNAPSHOT: BAXTER INTERNATIONAL INC. 139
FIGURE 37 COMPANY SNAPSHOT: JOHNSON & JOHNSON 142
FIGURE 38 COMPANY SNAPSHOT: C.R. BARD, INC. 146
FIGURE 39 COMPANY SNAPSHOT: COVIDIEN PLC. 150
FIGURE 40 COMPANY SNAPSHOT: SANOFI GROUP 154
FIGURE 41 COMPANY SNAPSHOT: B. BRAUN MELSUNGEN AG 157
FIGURE 42 COMPANY SNAPSHOT: GETINGE GROUP 159
FIGURE 43 COMPANY SNAPSHOT: CRYOLIFE, INC. 161
FIGURE 44 COMPANY SNAPSHOT: STRYKER CORPORATION 164
“
